Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Assess efficacy of FDC vs. ezetimibe vs. placebo for 12 week LDL-C lowering, changes in
atherogenic lipids, hsCRP and exploratory glycemic measures as well as safety in patients
with type 2 diabetes and elevated LDL-C.

Inclusion Criteria:

- Type 2 diabetes for 6 months or greater

- Currently taking stable diabetes medication for 3 months or greater

- HbA1c between 7-10%

- LDL-cholesterol greater than 70 mg/dL

- Women must not be pregnant, lactating, or planning to become pregnant within 30 days
after last dose of study medication; and must be postmenopausal, surgically sterile,
or willing to use 1 acceptable form of birth control during the study through 30 days
after the last dose of study medication

Exclusion Criteria:

- Body mass index > 40 kg/m2

- History of documented clinically significant cardiovascular disease

- Fasting triglycerides > 400 mg/dL

- History of Type 1 diabetes

- Uncontrolled hypothyroidism, liver dysfunction, renal dysfunction, gastrointestinal
condition that may affect drug absorption, hematologic or coagulation disorder or
active malignancy

- History of drug or alcohol abuse within 2 years